156 related articles for article (PubMed ID: 11371136)
1. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
[TBL] [Abstract][Full Text] [Related]
2. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
4. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
[TBL] [Abstract][Full Text] [Related]
7. The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose SL; Buller RE
Minerva Ginecol; 2002 Jun; 54(3):201-9. PubMed ID: 12063435
[TBL] [Abstract][Full Text] [Related]
8. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours.
Crook T; Brooks LA; Crossland S; Osin P; Barker KT; Waller J; Philp E; Smith PD; Yulug I; Peto J; Parker G; Allday MJ; Crompton MR; Gusterson BA
Oncogene; 1998 Oct; 17(13):1681-9. PubMed ID: 9796697
[TBL] [Abstract][Full Text] [Related]
9. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation.
Piek JM; Dorsman JC; Massuger LF; Ansink AC; Weegenaar J; Shvarts A; Kenemans P; Verheijen RH
Arch Gynecol Obstet; 2006 Oct; 274(6):327-31. PubMed ID: 16826413
[TBL] [Abstract][Full Text] [Related]
12. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE
Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.
Hartman AR; Ford JM
Nat Genet; 2002 Sep; 32(1):180-4. PubMed ID: 12195423
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
17. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin.
Sonoda Y; Saigo PE; Federici MG; Boyd J
Gynecol Oncol; 2000 Feb; 76(2):226-9. PubMed ID: 10637076
[TBL] [Abstract][Full Text] [Related]
18. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
19. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
Hakem R; de la Pompa JL; Elia A; Potter J; Mak TW
Nat Genet; 1997 Jul; 16(3):298-302. PubMed ID: 9207798
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.
Birgisdottir V; Stefansson OA; Bodvarsdottir SK; Hilmarsdottir H; Jonasson JG; Eyfjord JE
Breast Cancer Res; 2006; 8(4):R38. PubMed ID: 16846527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
